In short
This article discusses the ongoing clinical trials investigating the use of THIO (2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione) in combination with cemiplimab for patients with advanced non-small cell lung cancer (NSCLC). The trials aim to assess the safety, tolerability, and effectiveness of this treatment approach in patients who have progressed after previous therapies.
At a glance
- Study Type
- Multicenter, Open-Label, Dose-Finding, Phase 2 Study
- Treatment
- THIO sequenced with Cemiplimab (LIBTAYO®)
- Condition
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Primary Objectives
- 1. Determine safety and tolerability; 2. Assess efficacy
- Key Eligibility Criteria
- - Stage 3 or 4 NSCLC; - Progressed after prior treatment; - One prior treatment including anti-PD-1/PD-L1 agent; - Measurable disease; - Adequate organ function
- Primary Endpoints
- 1. Incidence of adverse events; 2. Objective Response Rate (ORR); 3. Disease Control Rate (DCR)
- THIO Administration
- Intravenous infusion, max daily dose 180 mg, max total dose 540 mg
What is THIO?
THIO is a new medication being studied for the treatment of advanced non-small cell lung cancer (NSCLC). Its full chemical name is 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione, which is quite a mouthful! It's described as a "synthetically modified small molecule nucleoside," which means it's a specially designed drug that mimics parts of our genetic material.
Medical Condition Treated
THIO is being studied to treat advanced non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer, accounting for about 80-85% of all lung cancers. "Advanced" typically refers to cancer that has spread beyond the lungs to other parts of the body (stage III or IV).
How THIO Works
While the exact mechanism isn't fully explained in the trial information, THIO is being studied in combination with another drug called cemiplimab (LIBTAYO®). Cemiplimab is an immunotherapy drug, which means it helps the body's immune system fight cancer cells. The researchers are investigating whether THIO can enhance the effects of immunotherapy in patients whose cancer has progressed after previous treatments.
Current Clinical Trial
THIO is currently being studied in a Phase 2 clinical trial. This trial is: Multicenter: conducted at multiple hospitals or research centers Open-label: both patients and doctors know which treatment is being given Dose-finding: trying to determine the best dose of the drug The main goals of this study are: To determine if THIO is safe and well-tolerated when given with cemiplimab To assess how effective THIO is in treating advanced NSCLC when combined with cemiplimab
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key points include: Be at least 18 years old Have stage III or IV NSCLC that has progressed after previous treatment Have received only one prior treatment for advanced NSCLC, which must have included an immunotherapy drug Have at least one measurable tumor Have good overall health and organ function There are also several conditions that would prevent a person from participating, such as certain autoimmune diseases, untreated brain metastases, or active infections.
Potential Side Effects
As this is an ongoing study, the full range of side effects isn't yet known. However, the researchers are closely monitoring for any adverse events (negative side effects) during the trial. They're particularly watching for what they call dose-limiting toxicities (DLTs), which are side effects severe enough to limit how much of the drug can be given safely.
Conclusion
THIO represents a potential new treatment option for patients with advanced non-small cell lung cancer who have already tried other treatments. While it's still in the research phase, this clinical trial will help determine if THIO is safe and effective when combined with immunotherapy. As always, patients should discuss any new treatment options with their healthcare provider to determine what's best for their individual situation.